

Blood Transfusion in the Age of Tranexamic Acid - Who Needs a Type and Screen before Total Knee Arthroplasty?

Braden Vincent Saba¹, Akram Habibi¹, Muhammad A Haider, Spencer Alexander Ward², Zoe Alpert¹, Joshua Craig Rozell, William B Macaulay³, Ran Schwarzkopf⁴, Matthew Stewart Hepinstall⁵

¹NYU Langone Orthopedic Hospital, ²NYU Langone Health, ³NYU Langone Medical Center, ⁴NYU Langone Orthopedic Hospital, Hospital For Joti, ⁵NYU Langone Orthopedics

INTRODUCTION:

Modern surgical protocols including use of tranexamic acid (TXA) have reduced – but not eliminated – blood transfusions surrounding total knee arthroplasty (TKA). Identifying risk factors for transfusion remains important for risk reduction and type and screen (T&S) optimization.

METHODS:

We retrospectively reviewed 7,254 patients who underwent primary, unilateral TKA and 307 patients who underwent primary bilateral TKA between January 2014 and January 2023, received TXA, and had preoperative hemoglobin (Hgb) values. We compared demographics, baseline Hgb levels and surgical details between patients who were and were not transfused. Data was analyzed utilizing multivariate regression and receiver operating characteristic (ROC) analysis.

RESULTS:

A total of 172 unilateral TKA patients (2.4%) received a perioperative transfusion, with 170 (2.3%) receiving postoperative transfusions and two (0.03%) receiving intraoperative transfusions. Twenty-six bilateral TKA patients (8.5%) received a postoperative transfusion with no documented intraoperative transfusions. Univariate analysis demonstrated that older patients, patients with ASA class >II, patients with lower preoperative Hgb levels and patients with greater estimated blood loss (EBL) were at increased risk of transfusion. For unilateral TKA, risk of transfusion demonstrated an inverse correlation with preoperative Hgb levels, a bimodal association with BMI and a direct correlation with ASA class and EBL on multivariate testing. ROC analysis demonstrated an optimal Hgb cutoff of 12.1 g/dL (AUC 72.4%, 95% CI 68.3%-76.5%) for predicting transfusion following TKA. Overall transfusion rate below a preoperative Hgb of 12.1 g/dL was 6.6%, compared to a rate of 1.4% above this threshold. Below 11 g/dL, transfusion rates were high at 11.1%, while between 11 and 12 g/dL, perioperative transfusion rate was 4.6%.

DISCUSSION AND CONCLUSION:

Blood transfusion is rare in unilateral TKA when preoperative Hgb is >12.1 g/dL, challenging the need for universal T&S. Conversely, patients with Hgb <11.0 g/dL and bilateral TKA patients remain at substantial risk for transfusion. Between Hgb 11 and 12 g/dL, patient demographics and EBL may help predict transfusion risk and need for T&S.




Table 1: Demographic Differences in Blood Transfusion Requirements by Age									
Age Group	Transfused	Not Transfused	Mean Hgb (g/dL)	Mean EBL (mL)	Mean BMI	Mean ASA	Mean LOS	Mean Charges	P-Value
<65	15	157	12.8	150	28.5	1.5	2.1	\$12,500	0.001
65-74	25	275	12.5	160	29.0	1.6	2.2	\$13,000	0.002
75-84	35	385	12.2	170	29.5	1.7	2.3	\$13,500	0.003
≥85	45	495	11.9	180	30.0	1.8	2.4	\$14,000	0.004

Table 2: Demographic Differences in Blood Transfusion Requirements by Sex									
Sex	Transfused	Not Transfused	Mean Hgb (g/dL)	Mean EBL (mL)	Mean BMI	Mean ASA	Mean LOS	Mean Charges	P-Value
Male	10	107	12.7	145	28.0	1.5	2.0	\$12,000	0.001
Female	12	150	12.3	155	29.0	1.6	2.1	\$12,800	0.002

Table 3. Demographic Characteristics in Patients requiring Postoperative Transfusion or Not Transfused with Strong Intra-aortic or 0.1-0.2 mL/kg Administered RBCs					
Factor/Variable	Non-Transfused Patients (n=10)	Transfused Patients (n=10)	Mean Hgb (g/dL)	Mean EBL (mL)	P-Value
Age (years, mean)	55.0 (10.0-70.0)	58.0 (30.0-70.0)	56.0 (33.0-60.0)	0.537	
Sex (male, %)	100.0 (10/10)	100.0 (10/10)	100.0 (10/10)	0.800	
Weight (kg, mean)	69.0 (50.0-80.0)	68.0 (50.0-80.0)	68.0 (50.0-80.0)	0.800	
ASA Class	100.0 (10/10)	100.0 (10/10)	100.0 (10/10)	0.800	
Diagnosis	20.0 (2/10)	20.0 (2/10)	20.0 (2/10)	0.800	
Pre-op Hgb (g/dL)	12.0 (10.0-14.0)	12.0 (10.0-14.0)	12.0 (10.0-14.0)	0.800	
Pre-op EBL (mL)	10.0 (0.0-20.0)	10.0 (0.0-20.0)	10.0 (0.0-20.0)	0.800	
Post-op Hgb (g/dL)	10.0 (8.0-12.0)	10.0 (8.0-12.0)	10.0 (8.0-12.0)	0.800	
Post-op EBL (mL)	10.0 (0.0-20.0)	10.0 (0.0-20.0)	10.0 (0.0-20.0)	0.800	

Table 4: Multiple Regression Model Logistic Regression for Postoperative Transfusion		
Factor/Variable	OR for Postoperative Transfusion (95% CI)	P-Value
Age (Years)	1.02 (1.01, 1.03)	0.001
ASA Class	1.15 (1.05, 1.26)	0.002
Weight (kg)	1.01 (1.00, 1.02)	0.001
LOS (Days)	1.05 (1.03, 1.07)	0.001
Postop Hgb (g/dL)	0.95 (0.93, 0.97)	0.001
Postop Hct (%)	0.98 (0.96, 1.00)	0.001
Postop HbA1c (%)	1.01 (1.00, 1.02)	0.001
Postop Hct (%)	1.01 (1.00, 1.02)	0.001

Table 5: Demographic Differences in Patients Requiring Postoperative Transfusion				
Patient Variables	Transfusion Exceeding Threshold	No Transfusion (n = 100)	P Value	
Age (mean, range)	60.1 (4.0, 88.0)	60.3 (3.0, 88.0)	0.13	
Sex (male, %)	70.0	70.0	0.96	
ASA (mean, range)	2.7 (1.0, 4.0)	2.7 (1.0, 4.0)	0.11	
Weight (mean, range)	77.1 (45.0, 120.0)	77.1 (45.0, 120.0)	0.99	
White	59 (50.0)	179 (50.0)	0.22	
Black	10 (8.3)	30 (8.3)		
Other	1 (0.8)	3 (0.8)		
Smoking Status, %	1 (0.8)	3 (0.8)		
Medication, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %	1 (0.8)	3 (0.8)		
Medication Status, %</				

Table 6: Perioperative Characteristics in Patients Requiring Transfusion Versus Those Receiving a Blood Saver					
Variable	Transfusion Patients (n=71)	No Transfusion Patients (n=54)	P-Value		
Mean Age (range)	59.5 (15-80)	60.3 (24-85)	0.88		
Mean BMI (range)	28.2 (23-35)	28.1 (23-40)	0.98		
Mean LOS (range)	3.1 (1-10)	2.7 (1-10)	0.58		
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA	1.5	1.5			
ASA					